Jin Lü, PhD, is a Research Assistant Professor in Prof. Liwei Xie's group at the faculty of Synthetic Biology, Shenzhen University of Advanced Technology. He obtained his PhD from the State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University. He completed postdoctoral training at Shenzhen Bay Laboratory and Hong Kong Baptist University. His research focuses on microbial chassis engineering, discovery of antibacterial and anti-tumor natural products, GPCR-targeted intestinal metabolites, and development of candidate antibodies for diabetes. His ongoing work centers on synthetic biology-enabled functional microbial development, including engineered probiotic chassis construction (living biotherapeutics) and microbial natural product discovery (anti-tumor, antibacterial, anti-obesity and hypoglycemic compounds). He aims to translate microbial resources into disease intervention and industrial applications. He has published multiple SCI papers in journals including Synth Syst Biotechnol, Front Microbiol, and Cell Chem Biol, and holds one authorized patent.

1.Engineeringof microbial chassis (including probiotics) for biomanufacturing and in-vivo intestinal applications

2.Discovery and application of antibacterial, anti-tumor, hypoglycemic and hypolipidemic natural products

Education:

2013–2021: Shanghai Jiao Tong University, Biology, Ph.D. in Biology (Supervisor: Prof. Meifeng Tao)

2010–2013: Central China Normal University, Microbiology, MSc in Microbiology, Supervisor: Prof. Aiying Li

2007–2009: Wuhan Polytechnic University, Bioengineering, B.Sc. in Bioengineering

Work Experience:

2023.09–2026.04: Postdoctoral Fellow, School of Chinese Medicine, Hong Kong Baptist University (Prof. Hoi Leong Xavier Wong's Group)

2021.02–2022.02: Postdoctoral Fellow, Institute of Neurodegenerative Diseases, Shenzhen Bay Laboratory (Prof. Wu Lin's Group)

Research Projects:

1.Innovation and Technology Support Programme (Hong Kong), Dissecting the therapeutic role of 3A2 antibody for the treatment of Obesity and Type 2 Diabetes, 2023/10–2026/04, Principal Investigator: Prof. Hoi Leong Xavier Wong

2.National Natural Science Foundation of China, General Program, Grant No. 32171252, Catalytic Mechanism of Human Fatty Acid Synthase and Iterative Lovastatin Polyketide Synthase, 2022–2025, Project Manager: Prof. Zixin Deng

3.National Key R&D Program of China, Grant No. 2018YFA0901901, Intelligent Mining of Novel Elements, Pathways and Structures of Natural Products, 2018–2021, Project Manager: Prof. Meifeng Tao

4.National Natural Science Foundation of China, Grant No. 31770036, Bacteriostatic Mechanism of Type V Lantibiotic Recapeptin, 2018–2021, Project Manager: Prof. Meifeng Tao

5.National Natural Science Foundation of China, Grant No. 31170050, Biological Mechanism of Novel Streptomyces Regulator Med-ORF10 Involved in Biosynthesis of Anti-tumor Antibiotic Medermycin, 2012–2015, Project Manager: Prof. Aiying Li

Selected publications:

1.He W,Lü J, Bai L, Deng Z, Tao M. dTSR enables efficient improvement of heterologous production of spinosad in Saccharopolyspora erythraea. Synth Syst Biotechnol. 2025 Apr 9;10(3):868-875. doi: 10.1016/j.synbio.2025.02.003. PMID: 40337009; PMCID: PMC12056787

2.Lü J, Long Q, Zhao Z, Chen L, He W, Hong J, Liu K, Wang Y, Pang X, Deng Z, Tao M*. Engineering the Erythromycin-Producing Strain Saccharopolyspora erythraea HOE107 for the Heterologous Production of Polyketide Antibiotics. Front Microbiol. 2020;11:3061. doi:10.3389/fmicb.2020.593217

3.Peng Q, Gao G,Lü J, Long Q, Chen X, Zhang F, Xu M, Liu K, Wang Y, Deng Z, Li Z, Tao M*. Engineered Streptomyces lividans strains for optimal identification and expression of cryptic biosynthetic gene clusters. Front Microbiol. 2018;9:3042. doi:10.3389/fmicb.2018.03042

4.Chen X, Xu M,Lü J, Xu J, Wang Y, Lin S, Deng Z, Tao M*. Biosynthesis of tropolones in Streptomyces spp.: interweaving biosynthesis and degradation of phenylacetic acid and hydroxylations on the tropone ring. Appl Environ Microbiol. 2018;84(12):e00349-18. doi:10.1128/AEM.00349-18

5.Lü J, He Q, Huang L, Cai X, Guo W, He J, Zhang L, Li A*. Accumulation of a bioactive benzoisochromanequinone compound kalafungin by a wild type antitumor-medermycin-producing streptomycete strain. PLoS One. 2015 Feb 19;10(2):e0117690. doi:10.1371/journal.pone.0117690

Other Publications and Patents:

6.Gao G, Liu X, Xu M, Wang Y, Zhang F, Xu L,Lü J, Long Q, Kang Q, Ou HY, Wang Y, Rohr J, Deng Z, Jiang M, Lin S, Tao M*. Formation of an angular aromatic polyketide from a linear anthrene precursor via oxidative rearrangement. Cell Chem Biol. 2017;24(7):881-891.e4. doi:10.1016/j.chembiol.2017.06.008

7.Lü J, Wu X, Jiang Y, Cai X, Huang L, Yang Y, Wang H, Zeng A, Li A*. An extremophile Microbacterium strain and its protease production under alkaline conditions. J Basic Microbiol. 2014 May;54(5):378-385. doi: 10.1002/jobm.201200553

8.Hu XR, He WJ,Lü J, Wang YM, Tao MF. Construction of Amycolatopsis host and heterologous expression of secondary metabolic gene clusters. Journal of Huazhong Agricultural University, 2022,41(3).

9.Guo T, He BH, Zeng C,Lü J. Optimization of conditions for hydrolysis of rice straw with concentrated sulfuric acid. Journal of Southwest University (Natural Science Edition), 2011,33(2): 143-146.

10.Li Aiying,Lü Jin, Xu Jinghua, Zhang Youming, Li Ruijuan, Li Caiyun. An engineered strain for heterologous expression of alkaline protease from extreme environments and its application. Patent No.: ZL 2017 1 1459372.0